维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

8篇 您的检索式：作者名="Josbert"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Imaging the Efficacy of Anti-Inflammatory Liposomes in a Rabbit Model of Atherosclerosis by Non-Invasive Imaging显示文摘	Mark E. Lobatto Claudia Calcagno Josbert M. Metselaar Gert Storm Erik S.G. Stroes Zahi A. Fayad Willem J.M. Mulder	2012	Methods in Enzymology2012，，：	1
	2	Bone morphogenetic protein 2 is expressed by, and acts upon, mature epithelial cells in the colon显示文摘	James C.H. Hardwick Gijs R. Van Den Brink Sylvia A. Bleuming Isabel Ballester Jan.M.H. Van Den Brande Josbert J. Keller G.Johan A. Offerhaus Sander J.H. Van Deventer Maikel P. Peppelenbosch	2004	Gastroenterology2004，，：	1
	3	Liposome-Encapsulated Prednisolone Phosphate Inhibits Growth of Established Tumors in Mice显示文摘	Raymond M. Schiffelers Josbert M. Metselaar Marcel H.A.M. Fens Adri?nne P.C.A. Janssen Grietje Molema Gert Storm	2005	Neoplasia2005，，：	1
	4	Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice显示文摘	Manuela Banciu Raymond M. Schiffelers Marcel H.A.M. Fens Josbert M. Metselaar Gert Storm	2006	Journal of Controlled Release2006，，：	1
	5	Liposomal corticosteroids for the treatment of inflammatory disorders and cancer显示文摘	Burcin Ozbakir Bart J. Crielaard Josbert M. Metselaar Gert Storm Twan Lammers	2014	Journal of Controlled Release2014，，：	1
	6	Molecular analysis of sulindae -resistant adenomas in familial adenomatous polyposis 显示文摘	Josbert JK Johan AO Paul D	2001	Clin Cancer Res2001，7，：	1
	7	Fecal microbiota transplantation: facts and controversies显示文摘	Els van Nood Peter Speelman Max Nieuwdorp Josbert Keller	2014	Current Opinion in Gastroenterology2014，，1：	1
	8	Cost-effectiveness in Clostridium difficile treatment decision-making显示文摘AIM: To develop a framework for the clinical and health economic assessment for management of Clostridium difficile infection(CDI).METHODS: CDI has vast economic consequences emphasizing the need for innovative and cost effective solutions, which were aim of this study. A guidance model was developed for coverage decisions and guideline development in CDI. The model included pharmacotherapy with oral metronidazole or oral vancomycin, which is the mainstay for pharmacological treatment of CDI and is recommended by most treatment guidelines.RESULTS: A design for a patient-based cost-effectiveness model was developed, which can be used to estimate the cost-effectiveness of current and future treatment strategies in CDI. Patient-based outcomes were extrapolated to the population by including factors like, e.g., person-to-person transmission, isolation precautions and closing and cleaning wards of hospitals. CONCLUSION: The proposed framework for a population-based CDI model may be used for clinical and health economic assessments of CDI guidelines and coverage decisions for emerging treatments for CDI.	Mark JC Nuijten Josbert J Keller Caroline E Visser Ken Redekop Eric Claassen Peter Speelman Marja H Pronk	2015	World Journal of Clinical Cases2015，3，11：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费